AU2001272192A1 - Use of dammarane-type triterpenoid saponins - Google Patents
Use of dammarane-type triterpenoid saponinsInfo
- Publication number
- AU2001272192A1 AU2001272192A1 AU2001272192A AU7219201A AU2001272192A1 AU 2001272192 A1 AU2001272192 A1 AU 2001272192A1 AU 2001272192 A AU2001272192 A AU 2001272192A AU 7219201 A AU7219201 A AU 7219201A AU 2001272192 A1 AU2001272192 A1 AU 2001272192A1
- Authority
- AU
- Australia
- Prior art keywords
- bacopasaponin
- bacopa
- compound
- arabinopyranosyl
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000008130 triterpenoid saponins Chemical class 0.000 title claims description 58
- 241001465754 Metazoa Species 0.000 claims description 173
- 238000000034 method Methods 0.000 claims description 170
- 150000001875 compounds Chemical class 0.000 claims description 140
- 235000015418 Bacopa monnieria Nutrition 0.000 claims description 109
- 150000001720 carbohydrates Chemical group 0.000 claims description 105
- -1 pseudojujubogenin glycoside Chemical class 0.000 claims description 82
- 150000001457 metallic cations Chemical class 0.000 claims description 78
- 150000001336 alkenes Chemical class 0.000 claims description 52
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- 239000000178 monomer Substances 0.000 claims description 52
- 240000002999 Bacopa monnieri Species 0.000 claims description 46
- 241000196324 Embryophyta Species 0.000 claims description 46
- 239000000126 substance Substances 0.000 claims description 45
- 229930184882 bacopasaponin Natural products 0.000 claims description 41
- 235000013601 eggs Nutrition 0.000 claims description 39
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 38
- XXMXKZMQNIHTRQ-UHFFFAOYSA-N Pseudojujubogenin Natural products CC(=CC1COC23CC4(CO2)C(CCC5C6(C)CCC(O)C(C)(C)C6CCC45C)C3C1(C)O)C XXMXKZMQNIHTRQ-UHFFFAOYSA-N 0.000 claims description 37
- 230000002708 enhancing effect Effects 0.000 claims description 31
- 239000003674 animal food additive Substances 0.000 claims description 30
- 235000013336 milk Nutrition 0.000 claims description 28
- 239000008267 milk Substances 0.000 claims description 28
- 210000004080 milk Anatomy 0.000 claims description 28
- 229920002554 vinyl polymer Polymers 0.000 claims description 27
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 26
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 26
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 26
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 26
- 125000001589 carboacyl group Chemical group 0.000 claims description 26
- 150000001768 cations Chemical class 0.000 claims description 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 26
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 26
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 26
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims description 26
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 claims description 26
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 26
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 26
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 26
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 26
- ZOFQVMPJZHCDBS-MUUHSGPCSA-N 26fg38011g Chemical compound O([C@H]1[C@@H](O)CO[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@H]4[C@]5([C@@]3(CC[C@H]2C1(C)C)C)C[C@]1(OC5)OC[C@H]([C@]([C@@H]14)(C)O)C=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZOFQVMPJZHCDBS-MUUHSGPCSA-N 0.000 claims description 25
- RANQPHKSRUUPKK-UHFFFAOYSA-N 3-O-[alpha-L-arabinofuranosyl-(1->2)-O-{beta-D-glucopyranosyl-(1->3)}-(alpha-L-arabinopyranosyl)]jujubogenin Natural products CC(C)=CC1CC(C)(O)C2C3CCC4C5(C)CCC(OC6OCC(O)C(OC7OC(CO)C(O)C(O)C7O)C6OC6OC(CO)C(O)C6O)C(C)(C)C5CCC4(C)C33COC2(C3)O1 RANQPHKSRUUPKK-UHFFFAOYSA-N 0.000 claims description 25
- AGYKYCQDUUPCBZ-ATCHUTDRSA-N bacopasaponin A Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)CO1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@]45[C@@H]([C@H]6[C@](O[C@@H]7[C@@H](O)[C@@H](O)[C@@H](O)CO7)(C)C[C@H](/C=C(\C)/C)O[C@@]6(OC4)C5)CC3)CC2)CC1 AGYKYCQDUUPCBZ-ATCHUTDRSA-N 0.000 claims description 25
- ZOFQVMPJZHCDBS-UHFFFAOYSA-N bacopasaponin C Natural products C12C(O)(C)C(C=C(C)C)COC2(OC2)CC2(C2(CCC3C4(C)C)C)C1CCC2C3(C)CCC4OC(C1OC2C(C(O)C(CO)O2)O)OCC(O)C1OC1OC(CO)C(O)C(O)C1O ZOFQVMPJZHCDBS-UHFFFAOYSA-N 0.000 claims description 25
- YQZSIEQEOMZVSW-UHFFFAOYSA-N bacopasaponin D Natural products CC(=CC1COC23CC4(CO2)C(CCC5C6(C)CCC(CC6C(C)(C)CC45C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C8O)C3C1(C)O)C YQZSIEQEOMZVSW-UHFFFAOYSA-N 0.000 claims description 25
- OPRGRYLKIPSETP-UHFFFAOYSA-N bacopasaponin E Natural products CC(=CC1CC(C)(OC2OCC(O)C(O)C2O)C3C4(C)CCC5C(CCC6C(C)(C)C(CCC56C)OC7OCC(O)C(OC8OC(CO)C(O)C(O)C8O)C7OC9OC(CO)C(O)C9O)C4%10COC3(C%10)O1)C OPRGRYLKIPSETP-UHFFFAOYSA-N 0.000 claims description 25
- 241000287828 Gallus gallus Species 0.000 claims description 24
- PMAKLEKVDHFGNE-UHFFFAOYSA-N bacopasaponin F Natural products CC(=CC1CC(C)(OC2OCC(O)C(O)C2O)C3C4(C)CCC5C(CCC6C(C)(C)C(CCC56C)OC7OC(CO)C(O)C(OC8OC(CO)C(O)C(O)C8O)C7OC9OC(CO)C(O)C9O)C4%10COC3(C%10)O1)C PMAKLEKVDHFGNE-UHFFFAOYSA-N 0.000 claims description 23
- KKXTYLIJLMOZCW-UHFFFAOYSA-N bacopaside VIII Natural products C12C3CCC4C5(C)CCC(OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)OC6C(C(O)C(CO)O6)O)C(C)(C)C5CCC4(C)C3(C3)COC23OC(C=C(C)C)CC1(C)OC1OCC(O)C(O)C1O KKXTYLIJLMOZCW-UHFFFAOYSA-N 0.000 claims description 23
- GHWPFBAAEVCXOY-UHFFFAOYSA-N bacopasaponin B Natural products CC(=CC1COC23CC4(CO2)C(CCC5C6(C)CCC(OC7OCC(O)C(O)C7OC8OC(CO)C(O)C8O)C(C)(C)C6CCC45C)C3C1(C)O)C GHWPFBAAEVCXOY-UHFFFAOYSA-N 0.000 claims description 22
- 235000013330 chicken meat Nutrition 0.000 claims description 22
- 244000187129 Bacopa monnieria Species 0.000 claims description 20
- 241000283690 Bos taurus Species 0.000 claims description 20
- 210000002268 wool Anatomy 0.000 claims description 20
- 235000013372 meat Nutrition 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 18
- 229930003231 vitamin Natural products 0.000 claims description 17
- 235000013343 vitamin Nutrition 0.000 claims description 17
- 239000011782 vitamin Substances 0.000 claims description 17
- 229940088594 vitamin Drugs 0.000 claims description 17
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 15
- 230000004083 survival effect Effects 0.000 claims description 14
- 235000019155 vitamin A Nutrition 0.000 claims description 14
- 239000011719 vitamin A Substances 0.000 claims description 14
- 229930182470 glycoside Natural products 0.000 claims description 13
- 241000295197 Bacopa caroliniana Species 0.000 claims description 12
- 241000742148 Bacopa eisenii Species 0.000 claims description 12
- 241000742149 Bacopa repens Species 0.000 claims description 12
- 241001102057 Bacopa rotundifolia Species 0.000 claims description 12
- 240000007948 Mecardonia procumbens Species 0.000 claims description 12
- 150000001298 alcohols Chemical class 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 150000002170 ethers Chemical class 0.000 claims description 12
- 150000004677 hydrates Chemical class 0.000 claims description 12
- 150000002989 phenols Chemical class 0.000 claims description 12
- 241000251468 Actinopterygii Species 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 10
- 244000144977 poultry Species 0.000 claims description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 9
- 241000283707 Capra Species 0.000 claims description 9
- 241001494479 Pecora Species 0.000 claims description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 9
- 229940045997 vitamin a Drugs 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 235000013365 dairy product Nutrition 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 244000052769 pathogen Species 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 235000019166 vitamin D Nutrition 0.000 claims description 7
- 239000011710 vitamin D Substances 0.000 claims description 7
- 241000238424 Crustacea Species 0.000 claims description 5
- 102000002322 Egg Proteins Human genes 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 210000003278 egg shell Anatomy 0.000 claims description 4
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 3
- 241000282838 Lama Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 241001416177 Vicugna pacos Species 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 3
- 235000014121 butter Nutrition 0.000 claims description 3
- 235000013367 dietary fats Nutrition 0.000 claims description 3
- 239000010520 ghee Substances 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 241000239290 Araneae Species 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 241000295198 Bacopa Species 0.000 claims 44
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 11
- 230000035764 nutrition Effects 0.000 claims 1
- 239000000284 extract Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 10
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 235000013594 poultry meat Nutrition 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 235000019688 fish Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 235000014590 basal diet Nutrition 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000012447 hatching Effects 0.000 description 7
- 244000144972 livestock Species 0.000 description 7
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000272517 Anseriformes Species 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000017448 oviposition Effects 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000255789 Bombyx mori Species 0.000 description 3
- 241000252233 Cyprinus carpio Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 241000272458 Numididae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 241000238565 lobster Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004151 Calcium iodate Substances 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000269779 Lates calcarifer Species 0.000 description 1
- 241000058338 Macrobrachium nipponense Species 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000832310 Palaemon macrodactylus Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241000907637 Penaeus semisulcatus Species 0.000 description 1
- 241000861914 Plecoglossus altivelis Species 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 241000269978 Pleuronectiformes Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241001533364 Portunus trituberculatus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000276699 Seriola Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- 235000009430 Thespesia populnea Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- VQLYBLABXAHUDN-UHFFFAOYSA-N bis(4-fluorophenyl)-methyl-(1,2,4-triazol-1-ylmethyl)silane;methyl n-(1h-benzimidazol-2-yl)carbamate Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1.C=1C=C(F)C=CC=1[Si](C=1C=CC(F)=CC=1)(C)CN1C=NC=N1 VQLYBLABXAHUDN-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- UHWJJLGTKIWIJO-UHFFFAOYSA-L calcium iodate Chemical compound [Ca+2].[O-]I(=O)=O.[O-]I(=O)=O UHWJJLGTKIWIJO-UHFFFAOYSA-L 0.000 description 1
- 235000019390 calcium iodate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- FHSWXOCOMAVQKE-UHFFFAOYSA-N phenylazanium;acetate Chemical compound CC([O-])=O.[NH3+]C1=CC=CC=C1 FHSWXOCOMAVQKE-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000019553 satiation Nutrition 0.000 description 1
- 238000009366 sericulture Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000020046 sherry Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-N sodium;1,1-dioxo-1,2-benzothiazol-3-one Chemical compound [Na+].C1=CC=C2C(=O)NS(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Fats And Perfumes (AREA)
- Medicines Containing Plant Substances (AREA)
Description
USE OF DAMMARANE-TYPE TRITERPENOID SAPONINS
FIELD OF THE INVENTION
THIS INVENTION relates generally to agents useful in the preparation of animal feed and pharmaceutical compositions for treating animals. More particularly, the invention relates to a feed additive, to animal feed, and to pharmaceutical compositions comprising a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof. The invention further relates to the use of the pharmaceutical composition or the feed inter alia for immunopotentiating and protecting an animal against infectious diseases, for promoting growth and development of an animal, for improving the production rate, weight and quality of poultry eggs, for improving the quality and yield of milk in livestock animals, for increasing the survival rate of aqueous animals or for" enhancing the hatch rate of eggs produced by aqueous animals.
BACKGROUND OF THE INVENTION
Bacopa monnieri L (Syn: Herpestis monnieri L., HB & K), Brahmi has been used for many years as a potent nerve tonic in the traditional Indian system of medicine (Chopra et al, 1956, In: Glossary of Indian Medicinal Plants, Council of Scientific and Industrial Research, New Delhi, page 32). Various extracts of this perennial creeping plant have been used to .enhance memory retention and to treat epilepsy and insomnia (Pandey et al 1967, Bhav Prakasάh Nighantu, page 461).
The activity associated with memory retention has been localised to the saponin- containing fraction of this plant (Chatterjee et al, 1963, Indian Journal of Chemistry 1: 212; Singh et al, 1988, Phytother. Res. 2: 70). The active saponin constituents have been designated bacopasaponins A, B, C, D, E and F (Chatterjee et al, 1965, Indian J. Chemistry 3: 24; Chatterjee et al, 1963, Indian J. Chemistry 1: 212; Basu et al, 1967, Indian J. Chemistry 5: 84; Rastogi et al, 1994, Phytochemistry 36: 133-137; Garai et al, 1996, Phytochemistry 42: 815-820; Garai et al, 1996, Phytochemistry 43: 447-449; Mahato et al, 2000, Phytochemistry 53(6): 711-714). Acid hydrolysis of the active saponin-containing fraction yields a mixture of aglycones, bacogenin Ai (Kulshreshtha et al, 1973, Phytochemistry 12: 887; Kawai et al, 1973, Acta Cryst 829: 2947), bacogenin
A (Kulshreshtha et al, 1974, Phytochemistry 12: 1205), bacogenin A3 (Chandel et al, 1997, Phytochemistry 16: 141) and bacogenin t (Kulshreshtha et al, 1973, Phytochemistry 12: 2074).
In work leading up to the present invention, it was unexpectedly discovered that one or more saponins, particularly bacopasaponins including their analogues and derivatives enhance the production of nitric oxide in animal cells and tissues. Nitric oxide has been shown to exert beneficial effects, by acting as an anti-bacterial, anti-parasitic, anti-viral agent or as a tumoricidal agent (e.g. Colasanti & Suzuki, 2000, Trends Pharmocol. Sci. 21(7): 249-252; Wallace & Miller, 2000, Gastroenterology 119(2) 512- 520); Pfaff et al, 2000, Parasite Immunol. 22(8): 397-405; Sherry et al, 2000, Mol Med. 6(6): 542-549; Pinelli et al, 2000, Vet. Parasitol 92(3): 181-189; Nappi et al, 2000, Nitric Oxide 4(4): 423-430; Shinde et al, 2000, Indian J Exp Biol 38(3): 201-210; Gobert et al, Infect. Immun. 68(8): 4653-4657; Taylor-Robinson, 2000, Med. Hypotheses 54(4): 638- 641). Apart from their nitric oxide producing property, the bacopasaponin compounds have also been found, quite unexpectedly, to improve the general well being of animals including reducing stress levels and to accelerate growth of animals. It has also been discovered that administering these compounds to poultry enhances their rate of egg production and the weight and quality of their eggs including enhanced eggshell strength. The bacopasaponin compounds have also been found to improve milk quality and milk yield and meat produced by livestock animals, to enhance the growth and quality of wool produced by wool producing animals such as sheep and goats and to improve the quantity and quality of silk produced by worms. It has also been discovered that these compounds have utility in enhancing the conversion, growth and survival rate of aqueous animals including farmed fish and crustaceans as well as the hatch rate of eggs produced by aqueous animals.
Having regard to the various beneficial effects produced either directly or indirectly by nitric oxide, and to the various other unexpected properties of the bacopasaponin compounds, the present discoveries have been reduced to practice in novel feed additives, feeds, pharmaceutical compositions and methods as described hereinafter.
SUMMARY OF THE INVENTION
Accordingly, in one aspect of the present invention, there is provided a feed additive for animals comprising a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these.
Suitably, the dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside. In a preferred embodiment, the darmnarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R and R are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising
at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from β-D- glucopyranosyl, /3-L-glucopyranosyl, c.-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg +, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
In a preferred embodiment, the compound is selected from bacopasaponin A, bacopasaponin B, bacopasaponin C and bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
Suitably, the compound is derived from a plant of the genus Bacopa. Preferably, said plant is Bacopa monnieri (Brahmi).
In a preferred embodiment, the compound is provided in the form of a saponin- containing extract or fraction of a plant of the genus Bacopa.
Preferably, the saponin-containing extract or fraction comprises at least one bacopasaponin selected from the group consisting of bacopasaponin A, bacopasaponin B, bacopasaponin C and bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
In another aspect, the invention contemplates an animal feed comprising the feed additive as broadly described above.
In yet another aspect, the invention features a method of increasing the egg laying rate of a bird, comprising feeding to the bird an animal feed comprising an egg laying rate enhancing effective amount of the compound as broadly described above.
In still yet another aspect, the invention encompasses a method of increasing the weight of eggs produced from a bird, comprising feeding to the bird an animal feed comprising an egg weight enhancing effective amount of the compound as broadly described above.
According to another aspect, the invention contemplates a method of enhancing the quality of eggs produced from a bird, comprising feeding to the bird an animal feed comprising an egg quality enhancing effective amount of the compound as broadly described above.
In a preferred embodiment, the improvement in the egg quality preferably relates to an increase in the omega fatty acid content of said eggs and/or the eggshell strength of said eggs.
In a related aspect, the invention resides in an egg produced by a bird which has been fed according to the method as broadly described above.
According to another aspect, the invention encompasses a method of increasing milk yield in an animal, comprising feeding to the animal an animal feed comprising a milk yield increasing effective amount of the compound as broadly described above.
In another aspect, the invention envisions a method of improving milk quality in an animal, comprising feeding to the animal an animal feed comprising a milk quality improving effective amount of a compound as broadly described above.
h a preferred embodiment, the improvement in the milk relates to an increase in the protein content of said milk.
In another embodiment, the improvement in the milk relates to an increase in the
Vitamin content of said milk, wherein the vitamin is selected from Vitamins A, D or E or combination of these. In a preferred embodiment, the vitamin is selected from Vitamins A orD.
In a related aspect, the invention extends to animal products obtained or derived from an animal which has been fed according to the method as broadly described above.
In one embodiment, the animal products are dairy products produced or derived from a milk-producing animal which has been fed with the animal feed as broadly described above. In a preferred embodiment of this type, the dairy product is selected from milk, butter, ghee, cheese, cream and yoghurt.
In yet another aspect, the invention provides a method of improving the quality of animal meat, comprising feeding to the animal an animal feed comprising a meat quality improving effective amount of the compound as broadly described above.
In a preferred embodiment, the improvement in the meat relates to an increase in the vitamin content of said meat, wherein the vitamin is selected from Vitamins A, D or E or combination of these. In a preferred embodiment, the vitamin is selected from Vitamins A or D. In an especially preferred embodiment, the vitamin is Vitamin A.
In a related aspect, the invention extends to meat obtained from an animal which has been fed according to the method as broadly described above.
In a preferred embodiment, the animal is selected from cattle, sheep, pigs, goats and poultry.
In an especially preferred embodiment, the meat is liver.
According to another aspect, the invention contemplates a method of enhancing the quality and/or quantity of wool, comprising feeding to a wool producing animal an animal feed comprising a wool quantity/quality enhancing effective amount of the compounds as broadly described above.
In a related aspect, the invention extends to wool obtained from a wool producing animal which has been fed according to the method as broadly described above.
Suitably, the wool producing animal is selected from sheep, goats, alpacas and llamas.
In another aspect, the invention features a method of improving the quality and/or quantity of silk produced by a silk producing animal, comprising feeding to said animal an animal feed comprising a silk quantity/quality improving effective amount of the compound as broadly described above.
In a related aspect, the invention extends to silk obtained from an animal which has been fed according to the method as broadly described above.
In a further aspect, the invention contemplates a method of enhancing the growth, conversion and/or survival rate of an aqueous animal, comprising feeding to the aqueous animal an animal feed comprising a growth, conversion and/or survival rate enhancing effective amount of the compound as broadly described above.
In another aspect, the invention encompasses a method of enhancing the hatch rate of eggs produced by an aqueous animal, comprising feeding to the aqueous animal an animal feed comprising an egg hatch rate enhancing effective amount of the compound as broadly described above.
In still a further aspect, the invention provides a pharmaceutical composition comprising the compound as broadly described above together with a pharmaceutically acceptable carrier or diluent.
In yet another aspect, the invention resides in a method for treating or preventing a condition associated with reduced nitric oxide levels in an animal, said method comprising administering to said animal an effective amount of the compound as broadly described above, optionally together with a pharmaceutically acceptable carrier or diluent, sufficient to inhibit or ameliorate said condition.
In a preferred embodiment, the condition is a stress-associated condition.
In another embodiment, the condition is associated with infection by a pathogenic organism.
In still yet another aspect, the invention features a method of improving the health of an animal, said method comprising administering to said animal a health-improving effective amount of the compound as broadly described above, optionally together with a
pharmaceutically acceptable carrier or diluent.
In a further aspect, the invention provides a method for enhancing the immune response of animal against infection by a pathogenic organism, said method comprising administering to said animal an immunity enhancing effective amount of the compound as broadly described, optionally together with a pharmaceutically acceptable carrier or diluent.
According to yet another aspect, the invention contemplates use of the compound as broadly described above in the preparation of compositions for treating or preventing a condition which is associated with reduced nitric oxide levels, or which is ameliorable or preventable by enhanced nitric oxide levels, within the body of an animal, or for promoting a response requiring enhanced nitric oxide levels within the body of an animal, for improving animal produce or for increasing the growth, conversion and/or survival rate of aqueous animals.
DETAILED DESCRIPTION OF THE INVENTION
1. Definitions
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. For the purposes of the present invention, the following terms are defined below.
The articles "a " and "an " are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
The term "about" is used herein to refer to the amount, weight or concentration of an active or substance that vary by as much as 30%, preferably by as much as 20%, and more preferably by as much as 10% to a reference amount, weight or concentration.
By "animal" is meant livestock animals (eg. sheep, cows, goats, horses, donkeys, pigs), laboratory test animals (eg. rabbits, mice, rats, guinea pigs, hamsters), companion animals (eg. cats, dogs), captive wild animals (eg. foxes, deer, minks, dingoes), poultry (e.g. fowls, turkeys, wild ducks, quails, guinea fowls, ducks, geese and pigeons), and aqueous animals particularly farmed aqueous animals (e.g. crustaceans and vertebrate fish, such as salmon, catfish, lobster, shrimp and the like, both from fresh and salt water)
Throughout this specification, unless the context requires otherwise, the words "comprise", "comprises" and "comprising" will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements.
By "effective amount", in the context of improving a quality of an animal or a quality or quantity of an animal product or the growth, conversion and survival rate of an aqueous animal or treating or preventing a condition in an animal, is meant the administration of that amount of active to an animal, either in a single dose or as part of a series, that is effective for that improvement, treatment or prevention. The effective
amount will vary depending upon the health and physical condition of the animal to be treated, the taxonomic group of the animal to be treated, the formulation of the composition, the assessment of the condition, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.
By "pharmaceutically acceptable carrier" is meant a solid or liquid filler, diluent or encapsulating substance that can be safely used in topical or systemic administration to a animal, preferably a mammal including humans.
2. Compositions and methods of the invention The present invention is generally directed to feed additives, feed and compositions comprising a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these. Surprisingly, these saponin compounds have been found to accelerate growth of animals, to improve the rate of egg production and to increase egg weight, egg quality of poultry, to enhance the quality and quantity of meat, milk quality and yield produced by livestock animals, to improve the quality and quantity of wool and silk produced respectively by wool producing and silk producing animals, and to enhance the conversion, growth and survival rate of aqueous animals, including farmed fish and crustaceans. Thus, the invention provides, in one aspect, a method for accelerating growth of an animal or for improving the egg laying rate, egg weight and egg quality of poultry, or for enhancing the meat and/or milk quality and quantity of livestock animals or for improving the quality and quantity of wool and silk produced respectively by wool producing and silk producing animals, or for enhancing the conversion, growth and survival rate of aqueous animals, or for enhancing the hatch rate of eggs produced by aqueous animals, by feeding to an animal an effective amount of an animal feed comprising a compound as described herein.
The dammarane-type triterpenoid saponin compounds of the invention have been found unexpectedly to enhance the production of nitric oxide in animal cells and tissues, which renders them useful for treating conditions associated with reduced nitric oxide
• levels in an animal or for producing beneficial effects in an animal which are ameliorable by increasing the nitric oxide levels in the animal. Thus, the invention also encompasses use of triterpenoid saponin compounds as described herein, optionally together with a
pharmaceutically acceptable carrier or diluent, for treating or preventing a condition associated with reduced nitric oxide levels in an animal, or for improving the health or general well being of an animal, or for enhancing the immune response of an animal against infection by a pathogenic organism.
The dammarane-type triterpenoid saponin is suitably a pseudojujubogenin glycoside. In a preferred embodiment, the dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R1 and R3 are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from β-D- glucopyranosyl, β-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl,
isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
In a preferred embodiment of compound (1) including derivatives thereof, R1 is 3- O-α-L-arabinopyranosyl and R2 is 20-O-α-L-arabinopyranosyl.
In a preferred embodiment of compound (II) including derivatives thereof, R1 is selected from the group consisting of 3-O-fα-L-arabinopyranosyl (1-2) - arabmopyranosyl], 3-O-[β-D-glucopyranosyl (1-3) {α-L-arabinofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) /3-D-glucopyranosyl] pseudojujubogenin and R is H.
In a preferred embodiment of compounds (III) including derivatives respectively thereof, R1 is H and R3 is H.
In a preferred embodiment of compounds (IV) and (V) including derivatives respectively thereof, R1 is H.
In an especially preferred embodiment, the compound is selected from bacopasaponin A, bacopasaponin B, bacopasaponin C and bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
Derivatives of the above compounds include, but not restricted to, ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, and any combination of two or more of the foregoing.
In another embodiment, one or more compounds as broadly described above are derived from a plant of the genus Bacopa and preferably from Bacopa monnieri (Brahmi) or a botanical or horticultural relative thereof. Thus, for the practice of the present invention in another embodiment, the invention contemplates the use of a chemical fraction comprising at least one dammarane-type triterpenoid saponin from a plant of the genus Bacopa or a derivative or analogue of said triterpenoid saponin having a structure as
defined above wherein said triterpenoid saponin or its derivative or chemical analogue modulates nitric oxide production in an animal. Reference herein to a plant of the genus Bacopa includes reference to Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta. Preferably, the chemical fraction is obtained from Bacopa monnieri.
In another embodiment, one or more of the aforementioned compounds may be purified from a plant of the genus Bacopa by any suitable method including the methods described for example by Chatterjee et al. (1963, Indian Journal of Chemistry 1: 212), Singh et al. (1988, Phytother. Res. 2: 70), Rastogi et al. (1994, Phytochemistry 36: 133- 137) Garai et al. (1996, Phytochemistry 42: 815-820), Garai et al. (1996, Phytochemistry 43: 447-449), Kulshreshtha et al. (1973, Phytochemistry 12: 887), Kawai et al. (1973, Ada Cryst 829: 2947), Kulshreshtha et al. (1974, Phytochemistry 12: 1205), Chandel et al. (1997, Phytochemistry 16: 141) and Kulshreshtha et al. (1973, Phytochemistry 12: 2074). An especially preferred chemical fraction of Bacopa monnieri (Brahmi) is described in Example 1.
The compounds of the present invention can be included as an additive to feed which suitably comprises a basal diet for feeding an animal. When the feed additive of the present invention is added to feed, it may be formulated along with feed components at the time of feed formulation, or may be added to feed at the time of feeding to animals. There is no limitation on the method and time of addition to feed. The arbitrary basal diet for animals, which is used for preparing the feed according to the invention, is not particularly limited. Examples of raw materials, which may constitute a basal diet include, but are not limited to, grains such as corn, milo and wheat flour, brans such as defatted rice bran and wheat bran, animal substances such as fish meal and skim milk, vegetable oil cake such as soybean oil cake, and additives such as calcium carbonate, calcium phosphate, common salt, DL-methionine, choline chloride, manganese sulfate, dry iron sulfate, calcium iodate, copper sulfate, dry zinc sulfate and sodium saccharin. The basal diet can be prepared by blending together such raw materials. Carbohydrates are also suggested for addition to the basal diet as a source of energy and as a filler, preferably in amounts ranging from 1% to 35% by weight of the total feed. The basal diet may also comprise a small amount of fat, such as fish oil, as an additional source of energy preferably in amounts ranging from 1% to 5% by weight of the total feed. The formulation of the basal diet will vary depending on
the animal to which the diet is fed. The feed may be in solid or liquid form. Supplemental vitamins, including additional ascorbic acid and Vitamin B2, minerals and trace elements sufficient to meet the daily nutritional requirements of the animal may be included in the feed as well as other compounds such as anti-microbiles and antibiotics registered for use with animals for consumption.
The novel feed formulation may be processed by any means now known or later developed in the art, including extrusion or pelleting techniques. Extrusion generally adds an amount of air to the final product, such that the flakes prepared by extrusion usually float when added to water. Pelleting, on the other hand, generally provides a dense pellet that sinks upon addition to water. The desired form of the final feed formulation will depend upon the species and feeding habits of the fish being cultivated.
It is preferred that the final processed feed has a moisture content ranging from 1 to 20% and preferably 3 to 12% by weight of the total feed to assure proper cohesion of the feed components. In general, the feed ingredients may have a sufficient natural moisture content to meet this objective, however additional water may be added to the feed mixture prior to processing if needed. In such event and according to conventional techniques, any excess moisture may then be removed from the processed feed by drying or by other means.
Other additives or adjuvants may also be added to the final processed feed as a coating where desired. For instance, it is known to coat processed feed pellets with an amount of oil or fat to enhance the water stability and cohesion of the pellets.
The improved feed of the present invention can be administered to various animals including, but not restricted to, livestock animals such as pig, cattle, horse, goat, sheep rabbit, llamas and alpacas, poultry such as chicken, quail, pigeon, guinea fowl, turkey, geese and duck, companion animals such as cats and dogs, silk producing animals such as worms and spiders as well as aqueous animals farmed in commercial fisheries, including vertebrate fish such as barramundi, carp, salmon, yellowtail, sea bream, flatfish, globefish, hardtail, amberjack, sweetfish and trout, and crustaceans such as lobster, crayfish, king prawn, Oriental shrimp, giant tiger shrimp, oriental river prawn, swimming crab, offshore greasy back prawn, green tiger prawn, stone crab, etc..
The feed additive and the animal feed of the present invention are useful for accelerating growth of animals, for improving the quality (e.g., protein content, vitamin content) and quantity of fresh milk and meat produced by livestock animals such as cattle, goats and sheep, for improving the rate of egg production and to increase egg weight, egg quality of poultry, for improving the quality and quantity of wool and silk produced respectively by wool producing and silk producing animals, and for enhancing the conversion, growth and survival rate of aqueous animals. For such improvements or enhancements, the triterpenoid saponin compounds of the subject invention are present in said feed additive between about 0.05% by weight and about 25% by weight inclusive, preferably between about 0.1% and about 20% by weight. Typically, when using an extract or chemical fraction of a plant of the genus Bacopa (e.g., Bacopa monnieri (Brahmi)), preferably prepared as described herein, the final dried extract is used at a concentration in the range of between about 0.001 g per kg or feed and 50 g per kg of feed, preferably between about 0.01 g per kg of feed and about 5 g per kg of feed, more preferably between about 0.02 g per kg of feed and about 0.5 g per kg of feed. When desired, the compounds of the invention may be provided in combination with any other active ingredient(s) such as vitamins and minerals. Typically, concentrations in the range of about 0.1-20 g of or chemical fraction of a plant of the genus Bacopa (e.g., Bacopa monnieri (Brahmi)) prepared according to Example 1 per kg of feed have been found to be effective for said improvements and enhancements.
The actives of the invention are typically fed to animals at a daily dose of between about 0.02 and about 25 mg per kg body weight, preferably between about 0.02 and about 3 mg per kg body weight, more preferably between about 0.2 and about 1.5 mg per kg of body weight. Typically, when using an extract or chemical fraction of a plant of the genus Bacopa (e.g., Bacopa monnieri (Brahmi)), preferably prepared as described herein, the final dried extract is fed to an animal at a daily dose of between about 0.2 and about 250 mg per kg body weight, preferably between about 0.2 mg and about 30 mg per kg of body weight, more preferably between about 2 mg and about 15 mg per kg of body weight.
With regard to feeding aqueous animals, these can be fed one or more times per day to satiation by manually broadcasting the novel triterpenoid saponin supplemented feed formulation or the feed additive itself, comprising essentially at least one triterpenoid saponin compound of the invention, across the surface of the water or automatically from
mechanical feeders. In order to achieve maximum growth, conversion and survival rates in accordance with this invention, the daily nutrient requirements of the aqueous animals must be met. In addition, disease and water quality management techniques should be utilised to provide a healthy and stress free environment for normal growth and development.
The compounds of the present invention can also be used as active(s) for treating conditions associated with reduced nitric oxide levels in an animal or for producing beneficial effects in an animal which are ameliorable by enhancing the nitric oxide levels in an animal. In a preferred embodiment, the condition is a stress-related condition. In this respect, the stress-related condition may be caused for example, by placing an animal in a confined space (e.g. cage, hatchery etc).
The actives of the present invention also have the effect of enhancing the immune function of an animal, and serve as preventive and therapeutic agents for various maladies and infectious diseases by virtue of this effect and thus the diseases against which this composition or agent is efficacious are not particularly limited.
The actives can be administered to an animal either by themselves or in pharmaceutical compositions where they are mixed with a suitable pharmaceutically acceptable carrier. Accordingly, the invention also provides a composition for effecting the above treatments, improvements and enhancements comprising dammarane-type triterpenoid saponin as broadly described above, together with a pharmaceutically acceptable carrier.
Depending on the specific conditions being treated, the active(s) may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa., latest edition. Suitable routes may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. For injection, the therapeutic agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the
barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. Intra-muscular and subcutaneous injection is appropriate, for example, for administration of immunogenic compositions and vaccines.
The agents can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated in dosage forms such as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. These carriers may be selected from sugars, starches, cellulose and its derivatives, malt, gelatine, talc, calcium sulphate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, and pyrogen-free water.
Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. The dose of agent administered to an animal should be sufficient to effect a beneficial response in the animal over time such as an increase in nitric oxide levels in the animal or an increase in the health of the animal, a decrease in the symptom(s) associated with stress or with infection by a pathogenic organism. The quantity of the active(s) to be administered may depend on the animal to be treated inclusive of the age, sex, weight and general health condition thereof. In this regard, precise amounts of the active(s) for administration will depend on the judgement of the practitioner. In determining the effective amount of the active to be administered in a said treatment, improvement or enhancement, the practitioner may evaluate the progression of a condition to be treated. In any event, those of skill in the art may readily determine suitable dosages of the active(s) of the invention.
Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipopbilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain
suitable stabilisers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as., for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymefhylcellύlose, and/or polyvinylpyrrohdone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pynolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association one or more therapeutic agents as described above with the carrier which constitutes one or more necessary ingredients. In general, the pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilising processes.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterise different combinations of active compound doses.
Pharmaceutical which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticiser, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilisers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilisers may be added.
Dosage forms of the therapeutic agents of the invention may also include injecting or implanting controlled releasing devices designed specifically for this purpose or other forms of implants modified to act additionally in this fashion. Controlled release of an agent of the invention may be effected by coating the same, for example, with hydrophobic polymers including acrylic resins, waxes, higher aliphatic alcohols, polylactic and polyglycolic acids and certain cellulose derivatives such as hydroxypropylmethyl cellulose. In addition, controlled release may be effected by using other polymer matrices, liposomes and/or microspheres.
The active(s) of the present invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms.
For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC50 as determined in cell culture (e.g., the concentration of active(s), which achieves a half-maximal enhancement in immune effector concentrations or a half-maximal inhibition is stress markers). Such information can be used to more accurately determine useful doses in animals.
Toxicity and therapeutic efficacy of such therapeutic agents can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds that exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies-can be used in formulating a range of dosage for use in animals. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilised. The exact formulation, route of administration and dosage can be
chosen by the individual practitioner in view of an animal's condition. (See for example Fingl et al, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 pi).
Dosage amount and interval may be adjusted individually to provide plasma levels of the active(s) which are sufficient to maintain immune effector enhancement or stress reducing effects. Stated in terms of body weight, usual dosages range from between about 0.02 and about 25 mg per kg per day, commonly between about 0.02 and about 3 mg per kg per day, typically between about 0.2 and 1.5 mg per kg per day.
Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a tissue often in a depot or sustained release formulation.
Furthermore, one may administer the active in a targeted drug delivery system, for example, in a liposome coated with tissue-specific antibody. The liposomes will be targeted to and taken up selectively by the tissue.
In cases of local administration or selective uptake, the effective local concentration of the active may not be related to plasma concentration.
In order that the invention may be readily understood and put into practical effect, particular preferred embodiments will now be described by way of the following non- limiting examples.
EXAMPLES
EXAMPLE 1
Preparation of bacopasaponin extract from Bacopa monnieri (Brahmi)
A sample of Bacopa monnieri (Brahmi) (l.Og) was macerated in 3 x 25-mL of dry acetone (dried over potassium carbonate). The macerate was filter/centrifuged each time and the residue was dried under vacuum. Ten milligrams of powdered extract was heated with 5 drops of orthophosphoric acid in a test tube (or until filter paper kept moist on the mouth of the test tube with aniline acetate turns pink).
Two hundred and fifty milligrams of powdered extract was hydrolysed by boiling with 4N; 50% (v/v) aqueous ethanolic sulphuric acid (5 mL). The ethanol was subsequently removed under vacuum. The aqueous suspension was extracted with two quantities, 5 mL each of freshly washed (phosgene free) chloroform. The combined chloroform layer was neutralised by washing with 0.1% (v/v) aqueous solution of ammonia, followed by 2 washes with water, followed by drying over anhydrous sodium sulphate and evaporating the solvent to dryness. The 0.001% (w/v) solution of the residue in methanol exhibited characteristic maxima at 269, 278 and 289 nm.
EXAMPLE 2
Chromatographic fingerprint of bacopasaponin extract
Thin layer chromatography was carried out using silica gel G plates of 0.2-mm thickness and a mixture of 8 parts of ethylacetate, 1 part methanol and 1 part water as the mobile phase. One mL of test solution containing the extract of Example 1 at about 1 μg/mL is then, added to 1 mL 4N aqueous sulphuric acid (A.R.). This mixture was refmxed on a water-bath for 4 hours, allowed to cool and diluted with 4 mL distilled water before the methanol was removed under vacuum. The aqueous solution was then extracted four times with chloroform (G.R., phosgene free) and the combined chloroform extract was washed with 0.1 % solution of a base (e.g. ammonia), followed by twice with distilled water. The extract was dried over anhydrous sodium sulphate and the chloroform removed under vacuum. The residue was dissolved in methanol (A.R.) up to a final volume of 10
mL. The optical density (O.D.) of the solution was then determined at 278 nm against a blank. The content of bacopasaponin in the extract was calculated by running reference standard bacopasaponins side by side, or by using the following linear regression curve formula:
C = KX O.D. + B
(where, C = concentration of bacopasaponin in μg/mL: K = 50.957 and B = 1.2974
EXAMPLE 3
Enhancing hatch rate offish eggs
Five hundred milligram of an extract prepared according to Example 1 containing 45 wt.% bacopasaponins was dispensed into 10 L of water containing 300 common carp (Cypnnus carpi o) eggs. The water was continuously aerated. The results presented in Table 1 show a significant increase in the percentage of eggs that hatched in the bacopasaponin-supplemented water (about 87%) relative to the control (about 57%). This represents an increase in egg hatchings of 65.4%.
TABLE 1
Number of eggs treated 300
Number of eggs in control 300
Number of hatchings in control 170
Number of hatchings in the bacopasaponin-supplemented water 260
Percentages of hatchings in control 56.67%
Percentage of hatchings in the bacopasaponin-supplemented 86.67% water
Further treatment of the fries for four weeks by addition of the same amount of extract with their normal solid fish feed increased the percentage survival of the fries to the
adult stage by about 35% relative to untreated fries (i.e., 80% of treated fries survived to the adult stage compared to 45% of untreated fries).
EXAMPLE 4
Enhancing growth rate offish
Extract prepared according to Example 1 was incorporated at a level of 0.5 mg/kg (feed-1) and 1 mgkg (feed-2) in a standard feed containing 40% protein. The feed was powdered and fed to common carp fish fries. The feeding trials were carried out in a trough with 10 litres of water. Ten fries were introduced in the trough. The water was aerated continuously and the faecal matters were cleaned daily. The fries were fed ad libitum. The experiment was carried out for a penod of 30 days. The results of the experiment are presented in Table 2:
TABLE 2
These results indicate that fish fed with the extract-containing feeds gained significantly more weight than fish fed with the control feed. In this regard, the mean weight gain of fish per day was 0.0021 g for feed-1, 0.0046 g for feed-2 and 0.0008 g for
the control. Accordingly, a greater than two-fold increase in growth of fish was obtained with feed-1 and a six-fold increase was obtained with feed-2 when compared to the control feed.
! EXAMPLE 5
Enhancing quality and quantity of milk produced by cows
Twenty weeks after parturition 200 Indian Jersey cows were divided into the following 2 groups of 100 cows and fed a designated feed for 12 weeks: Group A where the basic feed as listed in Table 3 was given; Group B where 500 mg per day of an extract prepared according to Example 1, containing 45 wt.% bacopasaponins, mixed with a basic feed listed in Table 3, was given. The animals took water ad libitum.
TABLE 3
The Group B (treated) cows produced 16% more milk compared to Group A (control) cows. Milk obtained from the treated cows had 17% more protein (3.77 g/100 mL compared to 3.22 g/100 mL of milk for control cows), 23% more fat and 93% more β- carotene (150 μg/mL compared to 285 μg/mL of milk for control cows). When the supply of extract-containing feed to the Group B treated cows was withdrawn, milk yields reduced to normal levels after 15 days. It was also found quite unexpectedly that use of the bacopasaponin extract as a feed additive could substantially reduce the fodder intake per cow by about 20-25% without significantly reducing the amount or quality of the milk produced.
It was also found that milk obtained from Group B cows after five days of treatment comprised about 5 times more Vitamin A, about 2 to 9 times more Vitamin D, and about 4 to 7 times more Vitamin E compared to milk obtained from Group A cows (Table 4).
TABLE 4
Dairy products (e.g., butter and ghee) produced from Group B cow milk contained significantly higher levels of Vitamin A as compared to dairy products produced from Group A cow milk (Table 5).
TABLE 5
EXAMPLE 6
Increasing the rate of weight gain in Broiler chickens
Twenty-five millilitres of a stock solution containing 5 mg/mL of an extract comprising 45 wt.% bacopasaponins prepared according to Example 1 was added twice daily to the common drinking water of 100 Broiler chickens. A control group of 100 chickens was given water only. The animals took water ad libitum. The treated chickens
attained their market weight of 1.5 kg at day 42 as compared to day 46-48 for control chickens. This resulted in a saving of 4-6 days of feed, which correlates to a 15-20% increase in economic gain. The treated chickens also showed a 50% reduction in the rate of mortality (4%) compared to control chickens (8-10%). It was also observed that the meat of treated chickens was appreciably leaner relative to control chickens.
EXAMPLE 7
Enhancing quantity anά quality of poultry eggs
Twenty-five millilirres of a stock solution containing 5 mg/mL of an extract comprising 45 wt.% bacopasaponins (prepared according to Example 1) was added twice daily to the common drinking water of 100 first cycle egg-laying chickens (i.e, chickens laying eggs for the first time). A control group of 100 first cycle-laying chickens was given water only. The animals took water ad libitum. Bacopasaponin treatment increased the number of chickens producing eggs by about 6% (i.e. 90% of control chickens as compared to 96% of treated chickens), increased egg weight by about 4% (i.e. from 55 to 57 g), increased /3-carotene of the egg yolk by about 3%, increased egg shell strength and reduced yolk cholesterol. The treatment also reduced feed consumption by about 3% and the rate of chicken mortality by about 50% as compared to control chickens.
A similar bacopasaponin treatment of 100 second cycle chickens ("culled chickens") increased the number of chickens producing eggs by about 31% (i.e. 65% of control chickens as compared to 85% of treated chickens).
EXAMPLE 8
Sericulture
Three hundred silk worms (treated group ) were fed mulberry leaves sprayed with glucose water containing 0.05 mg/mL of an extract comprising 45 wt.% bacopasaponins (prepared according to Example 1) three times daily from the fifth day after hatching until the end of their life cycle (about the twenty-fifth day after hatching). Three hundred control silk worms (control group) were fed mulberry leaves sprayed with glucose water only. The nest weight of the treated group (1.47 g) was about 34% higher relative to that
of the control group (1.20 g). Further, the thread produced by the treated silk worms was of a higher quality in that it was longer, darker and had more lustre (i.e. shine).
The percentage of worms that progressed to cocoon building was also higher in the treated group (93%) relative to the control group (67%). Mortality and non- productivity was also significantly reduced in the treated group.
EXAMPLE 9
Increasing Vitamin A content of beef
The basic feed listed in Table 3 supplemented with 500 mg of an extract prepared according to Example 1, containing 45 wt.% bacopasaponins was given daily to cattle for 15 days prior to slaughter. Beef, especially liver, obtained from these animals had a significantly higher Vitamin A content as compared to control animals fed with the basic feed alone.
The disclosure of every publication cited herein is hereby incorporated herein by reference in its entirety.
The citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application
Throughout the specification the aim has been to describe the preferred embodiments of the invention without limiting the invention to any one embodiment or specific collection of features. Those of skill in the art will therefore appreciate that, in light of the instant disclosure, various modifications and changes can be made in the particular embodiments exemplified without departing from the scope of the present invention. All such modifications and changes are intended to be included within the scope of the appended claims.
Claims (184)
1. A feed additive for animals, comprising a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these.
2. The feed additive of claim 1, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
3. The feed additive of claim 1, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R and R are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from /3-D- glucopyranosyl, β-L-glucopyranosyl, c-L-arabinopyranosyl, and c-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
4. The feed additive of claim 3, wherein said compound has the general formula (I), R1 is 3-O-α-L-arabinopyranosyl and R2 is 20-O-α-L-arabinopyranosyl.
5. The feed additive of claim 3, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinopyranosyl (1-2) - arabinopyranosyl], 3-O-[j3-D-glucopyranosyl (1-3) {α-L-arabinofuranosyl (1-2)} -L- arabinopyranosyl] and 3-O-[c-L-arabinofuranosyl (1-2) /3-D-glucopyranosyl] pseudojujubogenin and R2 is H.
6. The feed additive of claim 3, wherein said compound has the general formula (HI), R1 is H and R3 is H.
7. The feed additive of claim 3, wherein said compound has the general formula (TV) and Rl is H.
8. The feed additive of claim 3, wherein said compound has the general formula (V), R1 is H.
9. The feed additive of claim 1, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasapomn B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
10. The feed additive of claim 1, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
11. The feed additive of claim 1, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
12. The feed additive of claim 11, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
13. The feed additive of claim 11, wherein said plant is Bacopa monnieri (Brahmi).
14. The feed additive of claim 11, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
15. Use of a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these in the preparation of a feed additive for preparing animal feed or for improving animal produce or for increasing the growth, conversion and/or survival rate of aqueous animals.
16. The use of claim 15, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
17. The use of claim 15, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R1 and R3 are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from j8-D- glucopyranosyl, 3-L-glucopyranosyl, α-L-arabinopyranosyl, and Oi-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
18. The use of claim 17, wherein said compound has the general formula (I), R1 is 3-O-α- L-arabinopyranosyl and R2 is 20-O-α-L-arabinopyranosyl.
19. The use of claim 17, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinopyranosyl (1-2) - arabinopyranosyl], 3-O-[j3-D-glucopyranosyl (1-3) {α-L-arabinofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) 3-D-glucopyranosyl] pseudojujubogenin and R2 is H.
20. The use of claim 17, wherein said compound has the general formula (III), R1 is H and R3 is H.
21. The use of claim 17, wherein said compound has the general formula (TV) and R1 is H.
22. The use of claim 17, wherein said compound has the general formula (V), R1 is H.
23. The use of claim 15, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
24. The use of claim 15, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
25. The use of claim 15, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
26. The use of claim 25, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
27. The use of claim 25, wherein said plant is Bacopa monnieri (Brahmi).
28. The use of claim 25, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
29. An animal feed comprising said feed additive of claim 1.
30. An animal feed comprising said feed additive of claim 2.
31. An animal feed comprising said feed additive of claim 3.
32. An animal feed comprising said feed additive of claim 9.
33. An animal feed comprising said feed additive of claim 11.
34. .A method of increasing the egg production rate, egg weight, egg nutrition content or egg shell strength of a bird, comprising feeding to the bird an animal feed comprising an effective amount of a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these.
35. The method of claim 34, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
36. The method of claim 34, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R1 and R3 are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from /3-D- glucopyranosyl, j3-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg , Ca and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
37. The method of claim 36, wherein said compound has the general formula (I), R1 is 3- O-α-L-arabinopyranosyl and R2 is 20-O-α-L-arabinopyranosyl.
38. The method of claim 36, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinopyranosyl (1-2) α- arabinopyranosyl], 3-O-[j3-D-glucopyranosyl (1-3) {α-L-arabmofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) |3-D-glucopyranosyl] pseudojujubogenin and R i^ H.
39. The method of claim 36, wherein said compound has the general formula (III), R1 is H and R3 is H.
40. The method of claim 36, wherein said compound has the general formula (TV) and R1 is H.
41. The method of claim 36, wherein said compound has the general formula (V), R1 is H.
42. The method of claim 34, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
43. The method of claim 34, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
44. The method of claim 34, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
45. The method of claim 44, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
46. The method of claim 44, wherein said plant is Bacopa monnieri (Brahmi).
47. The method of claim 44, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasapomn F, or analogue or derivative thereof.
48. The method of claim 34, wherein said bird is a chicken.
49. A method of increasing the yield, protein content or vitamin content of milk produced by an animal, comprising feeding to the animal an animal feed comprising an effective amount of a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these.
50. The method of claim 49, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
51. The method of claim 49, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R1 and R3 are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+- and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from /3-D- glucopyranosyl, (3-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
52. The method of claim 51, wherein said compound has the general formula (I), R1 is 3- O-α-L-arabinopyranosyl and R2 is 20-O-α-L-arabinoρyranosyl.
53. The method of claim 51, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinopyranosyl (1-2) α- arabinopyranosyl], 3 -O- [/3-D-glucopyranosyl (1-3) {α-L-arabinofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) 3-D-glucopyranosyl] pseudojujubogenin and R2 is H.
54. The method of claim 51, wherein said compound has the general formula (III), R1 is H and R3 is H.
55. The method of claim 51, wherein said compound has the general formula (TV) and R1 is H.
56. The method of claim 51, wherein said compound has the general formula (V), R1 is H.
57. The method of claim 49, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
58. The method of claim 49, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
59. The method of claim 49, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
60. The method of claim 59, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
61. The method of claim 59, wherein said plant is Bacopa monnieri (Brahmi).
62. The method of claim 59, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
63. The method of claim 49, wherein said animal is selected from a cow, goat or sheep.
64. The method of claim 49, wherein said animal is a cow.
65. The method of claim 49, wherein the vitamin is selected from Vitamin A, Vitamin D or Vitamin E.
66. The method of claim 49, wherein the vitamin is selected from Vitamin A or Vitamin D.
67. The method of claim 49, wherein the vitamin is Vitamin A.
68. A dairy product produced or derived from an animal which has been fed according to the method of claim 49.
69. The dairy product of claim 68, wherein said product is selected from milk, butter, ghee, cheese, cream and yoghurt.
70. The dairy product of claim 68, wherein said product is milk.
71. A method of improving the quality of animal meat, comprising feeding to the animal an animal feed comprising a meat quality improving effective amount of a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these.
72. The method of claim 71, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
73. The method of claim 71, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R1 and R3 are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from /3-D- glucopyranosyl, |3-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
74. The method of claim 73, wherein said compound has the general formula (I), R1 is 3- O-α-L-arabinopyranosyl and R2 is 20-O-α-L-arabinopyranosyl.
75. The method of claim 73, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinoρyranosyl (1-2) α- arabinopyranosyl], 3-O-[/3-D-glucopyranosyl (1-3) {α-L-arabinofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) 3-D-glucopyranosyl] pseudojujubogenin and R2 is H.
76. The method of claim 73, wherein said compound has the general formula (III), R1 is H and R3 is H.
77. The method of claim 73, wherein said compound has the general formula (TV) and R1 is H.
78. The method of claim 73, wherein said compound has the general formula (V), R1 is H.
79. The method of claim 71, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
80. The method of claim 71, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
81. The method of claim 71, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
82. The method of claim 81, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
83. The method of claim 81, wherein said plant is Bacopa monnieri (Brahmi).
84. The method of claim 81, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasapomn B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
85. The method of claim 71, wherein the animal is selected from cattle, sheep, pigs, goats and poultry.
86. The method of claim 71, wherein the improvement relates to an increase in the vitamin content of said meat, wherein said vitamin is selected from Vitamins A, D or E.
87. The method of claim 86, wherein said vitamin is Vitamin A.
88. Meat produced from an animal which has been fed according to the method of claim 71.
89. The meat of claim 86, wherein the meat is beef.
90. The meat of claim 87, wherein the meat is liver.
91. A method of enhancing the quality and/or quantity of wool, comprising feeding to a wool producing animal an animal feed comprising a wool quantity/quality enhancing effective amount of a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these.
92. The method of claim 91, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
93. The method of claim 91, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
1 '•I '
R and R are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from /3-D- glucopyranosyl, /3-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K , Na and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
94. The method of claim 93, wherein said compound has the general formula (I), R1 is 3- O-α-L-arabinopyranosyl and R2 is 20-O-α-L-arabinopyranosyl.
95. The method of claim 93, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinoρyranosyl (1-2) α- arabinopyranosyl], 3-O-[(3-D-glucopyranosyl (1-3) {α-L-arabmofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) /3-D-glucopyranosyl] pseudojujubogenin and R2 is H.
96. The method of claim 93, wherein said compound has the general formula (III), R1 is H and R3 is H.
97. The method of claim 93, wherein said compound has the general formula (IV) and R1 is H.
98. The method of claim 93, wherein said compound has the general formula (V), R1 is H.
99. The method of claim 91, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
100. The method of claim 91, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
101. The method of claim 91, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
102. The method of claim 101, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
103. The method of claim 101, wherein said plant is Bacopa monnieri (Brahmi).
104. The method of claim 101, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
105. The method of claim 91, wherein said wool producing animal is selected from sheep, goats, alpacas and llamas.
106. Wool obtained from a wool producing animal which has been fed according to the method of claim 91.
107. A method of improving the quality and or quantity of silk produced by a silk producing animal, comprising feeding to said animal an animal feed comprising a silk quantity/quality improving effective amount of a compound selected from a dammarane- type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these.
108. The method of claim 107, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
109. The method of claim 107, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R1 and R3 are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca + and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from 3-D- glucopyranosyl, /3-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K , Na and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
110. The method of claim 109, wherein said compound has the general formula (I), R1 is 3-O-α-L-arabinopy anosyl and R is 20-O-α-L-arabinopyranosyl.
111. The method of claim 109, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinopyranosyl (1-2) α- arabinopyranosyl], 3-O-[ 3-D-glucopyranosyl (1-3) {α-L-arabmofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) /3-D-glucopyranosyl] pseudojujubogenin and R2 is H.
112. The method of claim 109, wherein said compound has the general formula (III), R1 is H and R3 is H.
113. The method of claim 109, wherein said compound has the general formula (IV) and R1 is H.
114. The method of claim 105, wherein said compound has the general formula (V), R1 is H.
115. The method of claim 107, wherein said darnmarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
116. The method of claim 107, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
117. The method of claim 107, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
118. The method of claim 117, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
119. The method of claim 117, wherein said plant is Bacopa monnieri (Brahmi).
120. The method of claim 117, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
121. The method of claim 107, wherein said silk producing animal is selected from a spider or worm.
122. The method of claim 107, wherein said silk producing animal is a worm.
123. Silk obtained from a silk producing animal which has been fed according to the method of claim 107.
124. A method of enhancing the growth, conversion, egg hatch rate and/or survival rate of an aqueous animal, comprising feeding to the aqueous animal an animal feed comprising a growth, conversion and/or survival rate enhancing effective amount of a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these.
125. The method of claim 124, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
126. The method of claim 124, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R and R are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from /3-D- glucopyranosyl, /3-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
127. The method of claim 126, wherein said compound has the general formula (I), R1 is 3-O-α-L-arabinopyranosyl and R2 is 20-O-α-L-arabinopyranosyl.
128. The method of claim 126, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinopyranosyl (1-2) α- arabinopyranosyl], 3-O-[/3-D-glucopyranosyl (1-3) {α-L-arabinofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) /3-D-glucopyranosyl] pseudojujubogenin and R2 is H.
129. The method of claim 126, wherein said compound has the general formula (III), R1 is H and R3 is H.
130. The method of claim 126, wherein said compound has the general formula (TV) and R1 is H.
131. The method of claim 126, wherein said compound has the general formula (V), R1 is H.
132. The method of claim 124, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
133. The method of claim 124, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
134. The method of claim 124, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
135. The method of claim 134, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
136. The method of claim 134, wherein said plant is Bacopa monnieri (Brahmi).
137. The method of claim 134, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasapomn B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
138. The method of claim 124, wherein said aqueous animal is selected from fish or crustaceans.
139. Use of a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these in the preparation of a medicament for treating or preventing a condition associated with reduced nitric oxide levels in an animal.
140. The use of claim 139, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
141. The use of claim 139, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R and R are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from /3-D- glucopyranosyl, /3-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
142. The use of claim 141, wherein said compound has the general formula (I), R1 is 3- O-α-L-arabinopyranosyl and R2 is 20-O-α-L-arabinopyranosyl.
143. The use of claim 141, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinopyranosyl (1-2) α- arabinopyranosyl], 3-O-[/3-D-glucopyranosyl (1-3) {α-L-arabinofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) /3-D-glucopyranosyl] pseudojujubogenin and R2 is H.
144. The use of claim 141, wherein said compound has the general formula (III), R1 is H and R3 is H.
145. The use of claim 141, wherein said compound has the general formula (TV) and R1 is H.
146. The use of claim 141, wherein said compound has the general formula (V), R1 is H.
147. The use of claim 139, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
148. The use of claim 139, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
149. The use of claim 139, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
150. The use of claim 149, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
151. The use of claim 149, wherein said plant is Bacopa monnieri (Brahmi).
152. The use of claim 149, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
153. The use of claim 139, the condition is a stress-associated condition.
154. The use of claim 139, the condition is associated with infection by a pathogenic organism.
155. A method for treating or preventing a condition associated with reduced nitric oxide levels in an animal, said method comprising administering to said animal an effective amount of a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these, optionally together with a pharmaceutically acceptable carrier or diluent, sufficient to inhibit or ameliorate said condition.
156. The method of claim 155, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
157. The method of claim 155, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
R1 and R3 are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from /3-D- glucopyranosyl, /3-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
158. The method of claim 157, wherein said compound has the general formula (I), R1 is 3-O-α-L-arabinopyranosyl and R2 is 20-O-α-L-arabinopyranosyl.
159. The method of claim 157, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinopyranosyl (1-2) α- arabinopyranosyl], 3-O-[/3-D-glucopyranosyl (1-3) {α-L-arabinofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofuranosyl (1-2) /3-D-glucopyranosyl] pseudojujubogenin and R is H.
160. The method of claim 157, wherein said compound has the general formula (III), R1 is H and R3 is H.
161. The method of claim 157, wherein said compound has the general formula (TV) and R1 is H.
162. The method of claim 157, wherein said compound has the general formula (V), R1 is H.
163. The method of claim 155, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
164. The method of claim 155, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
165. The method of claim 155, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
166. The method of claim 165, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
167. The method of claim 165, wherein said plant is Bacopa monnieri (Brahmi) .
168. The method of claim 165, wherein said chemical fraction comprises at least one bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
169. The method of claim 155, wherein said condition is a stress-associated condition.
170. The method of claim 155, wherein said condition is associated with infection by a pathogenic organism.
171. A method for enhancing the immune response of animal against infection by a pathogenic organism, said method comprising administering to said animal an immunity enhancing effective amount of the a compound selected from a dammarane-type triterpenoid saponin or derivative or pharmaceutically acceptable salt thereof or combination of these, optionally together with a pharmaceutically acceptable carrier or diluent.
172. The method of claim 171, wherein said dammarane-type triterpenoid saponin is a pseudojujubogenin glycoside.
173. The method of claim 171, wherein said dammarane-type triterpenoid saponin is a compound represented by a general formula selected from the group of consisting of:
wherein:
1 "X
R and R are individually and independently selected from H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably selected from /3-D- glucopyranosyl, /3-L-glucopyranosyl, α-L-arabinopyranosyl, and α-L-arabinofuranosyl; and
R2 is H or any other cation, preferably a metallic cation, more preferably an alkaline metallic cation (such as K+, Na+ and the like) or alkaline earth metallic cation (such as Mg2+, Ca2+ and the like), lower alkyl including linear and branched alkyl (such as methyl, ethyl, propyl, isopropyl, isobutyl, isopentyl and the like), lower alkene including linear or branched alkenes (such as vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, isopentenyl, allyl and the like), lower alkanoyl (such as acetyl, propionyl and butyryl), benzyl, a carbohydrate moiety comprising at least one carbohydrate monomer, modified or unmodified, branched or unbranched, the carbohydrate moiety preferably comprising five membered ring structures, six membered ring structures or both, the carbohydrate monomer preferably comprising α-L-arabinopyranosyl.
174. The method of claim 173, wherein said compound has the general formula (I), R1 is 3-O-α-L-arabinopyranosyl and R is 20-O-α-L-arabmopyranosyl.
175. The method of claim 173, wherein said compound has the general formula (II), R1 is selected from the group consisting of 3-O-[α-L-arabinopyranosyl (1-2) α- arabinopyranosyl], 3-O-[/3-D-glucopyranosyl (1-3) {α-L-arabinofuranosyl (1-2)} α-L- arabinopyranosyl] and 3-O-[α-L-arabinofαranosyl (1-2) /3-D-glucopyranosyl] pseudojujubogenin and R2 is H.
176. The method of claim 173, wherein said compound has the general formula (III), R1 is H and R3 is H.
177. The method of claim 173, wherein said compound has the general formula (TV) and R1 is H.
178. The method of claim 173, wherein said compound has the general formula (V), R1 is H.
179. The method of claim 171, wherein said dammarane-type triterpenoid saponin is a bacopasaponin selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasapomn F, or analogue or derivative thereof.
180. The method of claim 171, wherein said derivative is selected from ethoxylate derivatives, propoxylate derivatives, hydrates, aldehyde derivatives, ester derivatives, ether derivatives, alcohol derivatives, phenol derivatives, amine derivatives, other biologically or chemically equivalent substances, or any combination of two or more of the foregoing.
181. The method of claim 171, wherein said compound is in the form of a chemical fraction derived from a plant of the genus Bacopa.
182. The method of claim 181, wherein said plant is selected from Bacopa caroliniana, Bacopa egensis, Bacopa eisenii, Bacopa innominata, Bacopa monnieri, Bacopa procumbens, Bacopa repens, Bacopa rotundifolia and Bacopa stricta.
183. The method of claim 181, wherein said plant is Bacopa monnieri (Brahmi).
184. The method of claim 181, wherein said chemical fraction comprises at least one bacopasapomn selected from bacopasaponin A, bacopasaponin B, bacopasaponin C, bacopasaponin D, bacopasaponin E, bacopasaponin F, or analogue or derivative thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001272192A AU2001272192A1 (en) | 2000-07-12 | 2001-07-12 | Use of dammarane-type triterpenoid saponins |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ8751 | 2000-07-12 | ||
AUPQ8751A AUPQ875100A0 (en) | 2000-07-12 | 2000-07-12 | Novel way of increasing the biological nitric oxide (no) by herbal molecule bacosides (herb bacopa) and living and increasing animal yield |
AUPR0682 | 2000-10-11 | ||
AUPR0682A AUPR068200A0 (en) | 2000-10-11 | 2000-10-11 | Animal feed and compositions |
AU2001272192A AU2001272192A1 (en) | 2000-07-12 | 2001-07-12 | Use of dammarane-type triterpenoid saponins |
PCT/AU2001/000836 WO2002003813A1 (en) | 2000-07-12 | 2001-07-12 | Use of dammarane-type triterpenoid saponins |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001272192A1 true AU2001272192A1 (en) | 2002-01-21 |
Family
ID=27155977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001272192A Abandoned AU2001272192A1 (en) | 2000-07-12 | 2001-07-12 | Use of dammarane-type triterpenoid saponins |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2001272192A1 (en) |
-
2001
- 2001-07-12 AU AU2001272192A patent/AU2001272192A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11517551B2 (en) | Lactylates for the prevention and treatment of infections caused by gram-positive bacteria in animals | |
Allcroft | Chapter IX. Aflatoxicosis in farm animals | |
WO1995034218A1 (en) | Feed containing crude drug | |
US20120071557A1 (en) | Animal feed compositions of abscisic acid | |
KR950011734B1 (en) | Feed and feed additive for livestock poultry and fish for increasing disease, pseudorabies resistance | |
JP2013532993A (en) | Lauric acid distillate for animal feed | |
WO2002003813A1 (en) | Use of dammarane-type triterpenoid saponins | |
JP3534792B2 (en) | Disease resistant feed | |
US7045150B2 (en) | Tellurium containing nutrient formulation and process for enhancing the cumulative weight gain or feed efficacy in poultry | |
US20190191740A1 (en) | Methods to Promote Growth and Improve Feed Conversion in Animals | |
US20170252386A1 (en) | Method for feeding poultry | |
US20150037439A1 (en) | Phytogenic nutraceutical composition and methods of use thereof | |
AU2001272192A1 (en) | Use of dammarane-type triterpenoid saponins | |
JP2813471B2 (en) | Crude drug-containing feed | |
JP2001081034A (en) | Antiprotozoal agent for animal | |
WO2017143667A1 (en) | Feed composition and applications thereof in preparing animal feed additive | |
KR100608153B1 (en) | Method of rearing and feeds | |
JP2583382B2 (en) | Livestock and poultry feed containing purslane | |
JP2669908B2 (en) | Epidermis protector for fish | |
JP2599162B2 (en) | Prevention and treatment of Salmonella enteritidis infection in livestock and poultry | |
JPH10165109A (en) | Feed composition and feed | |
JPH06327412A (en) | Growth-promoting or improving feed and method | |
WO2019146825A1 (en) | Composition for preventing or treating parasitic infections in fish, comprising jerusalem artichoke extract or fraction thereof | |
JPH10179040A (en) | Feed composition and feed | |
Idowu et al. | Performance, digestiblity and carcass yield of broiler chickens fed diets containing two types of fishmeal |